Phenacemide

Anticonvulsant
  • N03AX07 (WHO)
Pharmacokinetic dataElimination half-life22–25 hoursIdentifiers
  • N-Carbamoyl-2-phenyl-acetamide
CAS Number
  • 63-98-9 checkY
PubChem CID
  • 4753
IUPHAR/BPS
  • 7265
DrugBank
  • DB01121 checkY
ChemSpider
  • 4589 checkY
UNII
  • PAI7J52V09
KEGG
  • D00504 checkY
ChEMBL
  • ChEMBL918 checkY
CompTox Dashboard (EPA)
  • DTXSID6023442 Edit this at Wikidata
ECHA InfoCard100.000.519 Edit this at WikidataChemical and physical dataFormulaC9H10N2O2Molar mass178.191 g·mol−13D model (JSmol)
  • Interactive image
  • O=C(NC(=O)N)Cc1ccccc1
InChI
  • InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13) checkY
  • Key:XPFRXWCVYUEORT-UHFFFAOYSA-N checkY
  (verify)

Phenacemide (INN, BAN) (brand name Phenurone), also known as phenylacetylurea, is an anticonvulsant of the ureide (acetylurea) class.[1] It is a congener and ring-opened analogue of phenytoin (a hydantoin),[2][3] and is structurally related to the barbiturates and to other hydantoins.[4] Phenacemide was introduced in 1949 for the treatment of epilepsy, but was eventually withdrawn due to toxicity.[2][3]

See also

References

  1. ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1578–. ISBN 978-0-412-46630-4.
  2. ^ a b Prasad JP (2010). "Central Nervous System". Conceptual Pharmacology. Universities Press. pp. 236–. ISBN 978-81-7371-679-9.
  3. ^ a b Saxena AK, Saxena M (1995). "Developments in anticonvulsants". In deStevens G, Zingel V, Leschke C, Hoeprich P, Schultz R, Mehrotra P, et al. (eds.). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Vol. 44. Basel: Birkhäuser. pp. 185–291. doi:10.1007/978-3-0348-7161-7_6. ISBN 978-3-0348-7161-7. PMID 7644666. {{cite book}}: |journal= ignored (help)
  4. ^ Kadam SS, Mahadik KR, Bothara KG (1 July 2007). "Central Nervous System Depresants". Principles of Medicinal Chemistry. Vol. II. Pragati Books Pvt. Ltd. pp. 147–. ISBN 978-81-85790-03-9.

Further reading

  • Coker SB (1986). "The use of phenacemide for intractable partial complex epilepsy in children". Pediatric Neurology. 2 (4): 230–232. doi:10.1016/0887-8994(86)90053-6. PMID 3508693.
  • Coker SB, Holmes EW, Egel RT (December 1987). "Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations". Neurology. 37 (12): 1861–1866. doi:10.1212/wnl.37.12.1861. PMID 3683877. S2CID 219205208.

External links

  • v
  • t
  • e
GABAergics
GABAAR PAMs
GABA-T inhibitors
Others
Channel
modulators
Sodium blockers
Calcium blockers
Potassium openers
Others
CA inhibitors
Others
  • v
  • t
  • e
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
  • GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific: ML-297 (VU0456810)
KCaTooltip Calcium-activated potassium channel
Blockers
  • BKCa-specific: Ethanol (alcohol)
  • GAL-021
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
  • Solnatide
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
  • See here instead.
LGICsTooltip Ligand gated ion channels
  • See here instead.
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
Stub icon

This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e